Financial results for 2007
Recruitment of CBO and start of operations in the USA
Turnover of 1.5 million euros for the first quarter of 2008
IPH 2301 enters into regulatory pre-clinical development
Results for Phase IIa study with IPH 1101 in mRCC
Innate Pharma will hold its AGM of Shareholders on June 27, 2008, in Marseilles
Encouraging data on IPH 1101 at the ASCO annual meeting
Total number of shares outstanding and voting rights, as of April 30, 2008
Outcome of the AGM that took place on June 27, 2008
IPH 1101 in combination with rituximab enters the second part of the Phase I/II trial in fNHL
